After Hours
$
40.16
Change
+0.02 +0.05%
Volume
Volume 11,510
Oct 28, 2016, 5:17 p.m.
Quotes are delayed by 20 min
Previous close
$ 40.42
$ 40.14
Change
-0.28 -0.69%
Day low
Day high
$40.01
$40.44
52 week low
52 week high
$37.82
$45.58
Market cap
$96.41B
Average volume
2.88M
P/E ratio
329.83
Rev. per Employee
$370,027
EPS
0.12
Dividend
0.46
Div yield
4.63%
Ex dividend date
11/2/16
MarketWatch News on GSK
-
GlaxoSmithKline profit buoyed by weaker pound
- MarketWatch.com
-
Novartis income up 7% on consumer-health JV
- MarketWatch.com
-
Index funds can be inferior to active funds in two crucial ways
- Philip van Doorn
-
GlaxoSmithKline seeks U.S. OK for shingles vaccine
- MarketWatch.com
-
GlaxoSmithKline names new consumer healthcare head
- MarketWatch.com
-
GlaxoSmithKline to sell remaining stake in Aspen
- MarketWatch.com
-
GlaxoSmithKline appoints Emma Walmsley next CEO
- MarketWatch.com
-
GlaxoSmithKline names first female CEO
- MarketWatch.com
-
GlaxoSmithKline names Emma Walmsley as next CEO
- MarketWatch.com
-
GlaxoSmithKline names Emma Walmsley as next CEO
- MarketWatch.com
-
4 Bargain Stocks Throwing Off Cash- Barrons.com
-
Google parent, Sanofi to set up diabetes JV Onduo
- MarketWatch.com
-
Glaxo submits sirukumab for European approval
- MarketWatch.com
-
FTSE 100 gains ground, supported by Yellen’s growth view
- Carla Mozee
-
FTSE 100 struggles as miners, drugmakers pull lower
- Carla Mozee
-
FTSE 100 snaps win streak, but miners cap losses
- Carla Mozee
- Loading more headlines...
Where does this data come from?
Analyst Estimates »
A data point based on hundreds of brokers buy, sell and hold rating.
Sentiment on GSK
Analyst Ratings
Other News on GSK
-
Here's Why Biogen Should Buy Ionis Pharmaceuticals
- Motley Fool
-
Tecfidera Continued to Lead in the Oral Multiple Sclerosis Market
- MarketRealist.com
-
Tysabri Continues to Witness Strong Growth in 3Q16
- MarketRealist.com
-
Merck & Co. Reports Growth in Its 3Q16 Earnings
- MarketRealist.com
-
UK 3rd-Quarter GDP Exceeded Expectations: Investors Gained 0.40%
- MarketRealist.com
-
3 Retirement Stocks to Buy in November
- Motley Fool
-
Why Fret Over Agenus Inc. Q3 Results?
- Motley Fool
-
Looking at the Portfolio of the Franklin Mutual European Fund
- MarketRealist.com
-
- Seeking Alpha
-
Glaxo Profit Jumps on Weaker Pound
- The Wall Street Journal Interactive Edition
-
Glaxo (GSK) Beats Q3 Earnings, Revenues Rise Y/Y
- Zacks.com
-
Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug
- MarketRealist.com
- Loading more headlines...
Earnings Announcement
Press Releases on GSK
-
International Coach Federation Announces 2016 Prism Award Honorees
- PR Newswire - PRF
-
Global Prostate Cancer Therapeutics Industry
- PR Newswire - PRF
-
Fighting Addiction and Other Unmet Medical Needs with Cannabidiol
- PR Newswire - PRF
-
Aptevo Therapeutics Augments Leadership Team
- GlobeNewswire
-
Global Prophylactic Human Vaccines Industry
- PR Newswire - PRF
-
US Healthcare Advertising Market Report & Forecast: 2016-2021
- PR Newswire - PRF
-
Global Foot Care Products Industry
- PR Newswire - PRF
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com
| Avg. APR | Last Week | 6 Months | |
|---|---|---|---|
| Low Interest | 12.00% | 12.00% | 11.96% |
| Business | 13.12% | 13.12% | 13.12% |
| Student | 13.42% | 13.42% | 13.42% |
| Balance Transfer | 14.41% | 14.41% | 14.39% |
| Airline | 15.13% | 15.13% | 15.17% |
| Reward | 15.24% | 15.24% | 15.30% |
| Cash Back | 15.33% | 15.33% | 15.30% |
| Instant Approval | 17.86% | 17.86% | 18.04% |
| Bad Credit | 22.86% | 22.86% | 22.56% |




